Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

News Daily News

Uninformed Consent? Most Patients Misunderstand True Benefits of PCI

Michael O'Riordan

November 29, 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

More Adverse Events, Higher Costs With Impella: New Observational Studies

News Conference News AHA 2019

More Adverse Events, Higher Costs With Impella: New Observational Studies

November 17, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

News Industry News

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

May 13, 2019

Unplanned Readmission Within 6 Months Affects 25% of PCI Patients in the US

News Daily News

Unplanned Readmission Within 6 Months Affects 25% of PCI Patients in the US

March 28, 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

March 17, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.